|
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
Sep 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
Apr 2024 |
Blood Advances |
Aplastic Anemia |
|
Modified Delphi panel consensus recommendations for management of severe aplastic anemia |
Aug 2024 |
Blood Advances |
Aplastic Anemia |
|
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
Jul 2023 |
Annals of Hematology |
Aplastic Anemia |
|
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
Apr 2019 |
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
|
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
Oct 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
